Assessment of early therapy discontinuation and health-related quality of life in breast cáncer patients treated with aromatase inhibitors: B-ABLE cohort study.

Breast Cancer Res Treat. 2019 May 24. doi: 10.1007/s10549-019-05289-7.

Pineda-Moncusí M, Servitja S, Tusquets I, Diez-Perez A, Rial A, Cos ML,Campodarve I, Rodriguez-Morera J, Garcia-Giralt N, Nogués X.

https://www.ncbi.nlm.nih.gov/pubmed/31127467
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen